Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 20/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 16/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30329300 | 1.00 | HCRTR2 (0.49) | HCRTR2HCRTR1 | |
| SCHEMBL25164553 | 0.89 | HCRTR2 (0.45) | HCRTR2HCRTR1 | |
| SCHEMBL30327799 | 0.89 | HCRTR2 (0.45) | HCRTR2HCRTR1 | |
| SCHEMBL30328816 | 0.87 | HCRTR2 (0.46) | HCRTR2HCRTR1 | |
| SCHEMBL25163494 | 0.87 | HCRTR2 (0.46) | HCRTR2HCRTR1 | |
| SCHEMBL25164132 | 0.87 | HCRTR2 (0.51) | HCRTR2HCRTR1 | |
| SCHEMBL30329359 | 0.87 | HCRTR2 (0.51) | HCRTR2HCRTR1 | |
| SCHEMBL25164599 | 0.87 | HCRTR2 (0.36) | HCRTR2HCRTR1 | |
| SCHEMBL30328204 | 0.87 | HCRTR2 (0.36) | HCRTR2HCRTR1 | |
| SCHEMBL25163993 | 0.86 | HCRTR2 (0.50) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | HCRTR2 2687/4885HCRTR1 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.